CDK4 and breast cancer: A total of 177 metastatic BC patients were enrolled in the study, of whom 66 (37.3%) were treated with CDK4/6 inhibitors plus letrozole and 111 (62.7%) were treated with CDK4/6 inhibitors and fulvestrant.